Home » Stocks » BVXV

BiondVax Pharmaceuticals Ltd. (BVXV)

Stock Price: $4.18 USD 0.20 (5.03%)
Updated Mar 1, 2021 11:35 AM EST - Market open
Market Cap 55.59M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 461.05M
EPS (ttm) -2.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 1
Last Price $4.18
Previous Close $3.98
Change ($) 0.20
Change (%) 5.03%
Day's Open 4.15
Day's Range 4.11 - 4.27
Day's Volume 88,789
52-Week Range 2.35 - 62.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 3 weeks ago

JERUSALEM, Israel, Feb. 2, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing pr...

PRNewsWire - 1 month ago

JERUSALEM, Jan. 29, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products ...

PRNewsWire - 1 month ago

JERUSALEM, Jan. 28, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products ...

PRNewsWire - 1 month ago

JERUSALEM, Jan. 28, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products ...

PRNewsWire - 1 month ago

JERUSALEM, Jan. 21, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on development and manufacturing of products for the prevention and t...

The Motley Fool - 4 months ago

The company reported negative results from a pivotal clinical trial.

24/7 Wall Street - 4 months ago

BlondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) was absolutely crushed on Friday after the company reported late-stage results from its flu vaccine study.

PRNewsWire - 4 months ago

JERUSALEM, Oct. 23, 2020 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a pioneer in the development of a universal flu vaccine designed to provide protection against current, f...

PRNewsWire - 4 months ago

JERUSALEM, Israel, Oct. 2, 2020 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the Phase 3 clinical trial M–001 universal influenza vaccine candidate ("BiondVax" or...

Seeking Alpha - 5 months ago

BiondVax Pharmaceuticals: A Small, Undervalued Biotech Company

PRNewsWire - 6 months ago

JERUSALEM, Aug. 20, 2020 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd.

PRNewsWire - 8 months ago

JERUSALEM, July 1, 2020 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) today announced that all participants in the placebo-controlled, blinded, pivotal, clinical efficacy, Phase...

PRNewsWire - 8 months ago

JERUSALEM, June 30, 2020 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal i...

PRNewsWire - 8 months ago

JERUSALEM, June 12, 2020 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal i...

PRNewsWire - 8 months ago

JERUSALEM, June 10, 2020 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) today announced the completion of the clinical study report (CSR) of a Phase 2 clinical trial of the Compa...

PRNewsWire - 9 months ago

JERUSALEM, May 20, 2020 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the M‑001 universal influenza vaccine candidate, today announced receipt of proceeds of appro...

About BVXV

BiondVax Pharmaceuticals, a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate is M-001, a synthetic peptide-based protein, which is in Phase III clinical trials for treatment of seasonal and pandemic strains of the influenza virus. The company was founded in 2003 and is headquartered in Jerusalem, Israel.

Industry
Biotechnology
Founded
2003
CEO
Ron Babecoff
Employees
25
Stock Exchange
NASDAQ
Ticker Symbol
BVXV
Full Company Profile

Financial Performance

Financial numbers in millions ILS.
Financial Statements